Announced Fri, 21 Aug · 08:52 IST
Glenmark's US arm launches Calcium Gluconate Injection in US market
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹2332.90
prior close
₹2334.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.7-1.0-1.2——————————
Up moveDown movePending
AI summary
Glenmark's US subsidiary has launched Calcium Gluconate Injection USP in three vial sizes for the US market. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi's approved drug. The target US market is around $69.9 million in annual sales per IQVIA data. This expands Glenmark's US injectables and hospital portfolio.
Likely market impact
Expands US injectables portfolio and adds a new revenue stream in a roughly $70 million US market opportunity.